Company profile: Mindset Pharma
1.1 - Company Overview
Company description
- Provider of drug discovery and development focused on creating optimized, patentable next-generation psilocybin-inspired medicines and novel psychedelic compounds to treat neurological and psychiatric disorders, developing serotonin 5-HT2A agonists for conditions such as treatment-resistant depression and PTSD.
Products and services
- Next-Generation Psilocybin-Inspired Medicines Development: Develops optimized and patentable next-generation psilocybin-inspired medicines to treat neurological and psychiatric disorders with unmet needs
- Drug Discovery of Psychedelic Compounds: Architects novel and patentable psychedelic compounds leveraging psilocybin inspiration to address unmet needs in neurological and psychiatric disorders
- Serotonin 5-HT2A Agonists: Engineers 5‑HT2A‑focused compounds that activate the serotonin 5‑HT2A receptor to treat treatment‑resistant depression and PTSD
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mindset Pharma
RemeGenix
HQ: United States
Website
- Description: Provider of development stage biotechnology focused on the commercialization of disease-altering therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RemeGenix company profile →
Roxro Pharma
HQ: United States
Website
- Description: Provider of intranasal pain-treatment drugs, offering ROX-888 for dental and postoperative pain and ROX-828, a non-opioid, non-triptan intranasal therapy for migraine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Roxro Pharma company profile →
Levicept
HQ: United Kingdom
Website
- Description: Provider of biological therapies for chronic pain, including LEVI-04 (p75NTR-Fc) for knee osteoarthritis that modulates the neurotrophin pathway to minimize side effects associated with anti-NGF antibodies, and a Phase II randomized, double-blind, placebo-controlled clinical trial assessing its efficacy, safety, and tolerability.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Levicept company profile →
Quadrant Biosciences
HQ: United States
Website
- Description: Provider of epigenetic diagnostics focused on early detection of neurological disorders, offering: a virtual pediatric clinic for autism evaluations via telehealth; molecular diagnostics for COVID-19, autism and Parkinson’s; autism assessment workflow software; and wastewater monitoring for SARS-CoV-2 and other pathogens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quadrant Biosciences company profile →
Santhera Pharmaceuticals
HQ: Switzerland
Website
- Description: Provider of pharmaceutical products for mitochondrial and neuromuscular diseases; develops and markets therapies for areas of high unmet medical need, including many orphan and niche indications with no current therapy, such as Vamorolone for Duchenne muscular dystrophy targeting inflammation and dystrophic cardiomyopathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Santhera Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mindset Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mindset Pharma
2.2 - Growth funds investing in similar companies to Mindset Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mindset Pharma
4.2 - Public trading comparable groups for Mindset Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →